Professor Martine Bagot and Professor Armand Bensussan, co-founder of OREGA Biotech, received the Galien Prize for their research leading to the development of lacutamab, a monoclonal antibody targeting the tumour antigen KIR3DL2, for patients with advanced, refractory and relapsed T-cell lymphomas, in particular erythrodermic cutaneous T-cell lymphomas.
The Galien Prize rewards two decades of research.